Companies are concerned one of the proposed biosimilar uptake drivers has been designed with only the bDMARDs in minds, will not work for other treatments, which will lead to even more policy change in the next 12 months.
Latest Video
New Stories
-
Let's make decisions based on credible information and not guesswork
April 24, 2024 - - Latest News -
Tour de Cure backs further development of Noxopharm's preclinical brain cancer candidate
April 24, 2024 - - Latest News -
Novartis nominates ex-BMS chief executive as its new chair
April 24, 2024 - - Latest News -
'The Pharmac system again, over about 33 years old, hasn’t really changed and evolved'
April 24, 2024 - - Latest News -
AusBiotech appoints experienced Sanofi leader as its new chief executive
April 23, 2024 - - Latest News -
Should principles such as 'equity' and 'opportunity cost' be applied consistently or not at all?
April 23, 2024 - - Latest News -
Rare Cancers Australia welcomes new appointments to its board of directors
April 23, 2024 - - Latest News